179 related articles for article (PubMed ID: 21448827)
1. [Malignant lymphoma: individualized treatment according to biological and clinical risk factors].
Dreyling M
Dtsch Med Wochenschr; 2011 Apr; 136(14):687-90. PubMed ID: 21448827
[No Abstract] [Full Text] [Related]
2. Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenström macroglobulinaemia.
Agathocleous A; Rohatiner A; Rule S; Hunter H; Kerr JP; Neeson SM; Matthews J; Strauss S; Montoto S; Johnson P; Radford J; Lister A
Br J Haematol; 2010 Nov; 151(4):346-53. PubMed ID: 20880120
[TBL] [Abstract][Full Text] [Related]
3. Phase 1 trial of bortezomib plus R-CHOP in previously untreated patients with aggressive non-Hodgkin lymphoma.
Furman RR; Martin P; Ruan J; Cheung YK; Vose JM; LaCasce AS; Elstrom R; Coleman M; Leonard JP
Cancer; 2010 Dec; 116(23):5432-9. PubMed ID: 20665890
[TBL] [Abstract][Full Text] [Related]
4. The role of serum immunoglobulin free light chain in response and progression in waldenstrom macroglobulinemia.
Leleu X; Xie W; Bagshaw M; Banwait R; Leduc R; Roper N; Weller E; Ghobrial IM
Clin Cancer Res; 2011 May; 17(9):3013-8. PubMed ID: 21415221
[TBL] [Abstract][Full Text] [Related]
5. Use of bortezomib in B-cell non-Hodgkin's lymphoma.
Wang M; Zhou Y; Zhang L; Nguyen CA; Romaguera J
Expert Rev Anticancer Ther; 2006 Jul; 6(7):983-91. PubMed ID: 16831071
[TBL] [Abstract][Full Text] [Related]
6. Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma.
Ruan J; Martin P; Furman RR; Lee SM; Cheung K; Vose JM; Lacasce A; Morrison J; Elstrom R; Ely S; Chadburn A; Cesarman E; Coleman M; Leonard JP
J Clin Oncol; 2011 Feb; 29(6):690-7. PubMed ID: 21189393
[TBL] [Abstract][Full Text] [Related]
7. Predictive biomarkers may help individualize treatment for patients with follicular lymphoma.
Barton MK
CA Cancer J Clin; 2013 Sep; 63(5):293-4. PubMed ID: 23842891
[No Abstract] [Full Text] [Related]
8. [Results of cytostatic therapy of malignant hemoblastoses].
Stacher A
Wien Z Inn Med; 1966 Jan; 47(1):1-16. PubMed ID: 4962311
[No Abstract] [Full Text] [Related]
9. Fourth biannual report of the Cochrane Haematological Malignancies Group.
Kober T; Hülsewede H; Bohlius J; Engert A
J Natl Cancer Inst; 2006 Apr; 98(8):E1. PubMed ID: 16622111
[No Abstract] [Full Text] [Related]
10. [Malignant lymphoma].
Mori T
Gan To Kagaku Ryoho; 2007 Feb; 34(2):162-6. PubMed ID: 17301521
[TBL] [Abstract][Full Text] [Related]
11. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
[No Abstract] [Full Text] [Related]
12. Sixteenth biannual report of the Cochrane Haematological Malignancies Group: focus on Non-Hodgkin's lymphoma.
Rancea M; Will A; Borchmann P; Monsef I; Engert A; Skoetz N
J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25031306
[TBL] [Abstract][Full Text] [Related]
13. [Subcutaneous administration of MabThera for therapy of non-Hodgkin lymphomas frees patients and medical personnel].
Pflege Z; 2013 Apr; 66(4):253. PubMed ID: 23634557
[No Abstract] [Full Text] [Related]
14. The challenge of recurrent follicular lymphoma.
Tomás JF
Lancet Oncol; 2011 Aug; 12(8):714-6. PubMed ID: 21724461
[No Abstract] [Full Text] [Related]
15. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
Collins-Burow B; Santos ES
Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
[TBL] [Abstract][Full Text] [Related]
16. [Chemotherapy and immuno-chemotherapy in malignant lymphoma].
Nishikori M; Nasu K; Shirakawa S; Karitani Y
Rinsho Ketsueki; 1983 Apr; 24(4):320-9. PubMed ID: 6350639
[No Abstract] [Full Text] [Related]
17. [Clinical development of a proteasome inhibitor, bortezomib, for the treatment of myeloma and lymphoma].
Tobinai K
Rinsho Ketsueki; 2007 Jun; 48(6):451-7. PubMed ID: 17633092
[No Abstract] [Full Text] [Related]
18. [Treatment of malignant lymphoma with single administration of BH-AC (N4-behenoyl-1-beta-D-arabinofuranosylcytosine].
Oguro M; Takagi T
Gan To Kagaku Ryoho; 1982 Mar; 9(3):508-15. PubMed ID: 6764108
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of chemotherapy CHOP vs. CHOP/VIA in the treatment of aggressive non-Hodgkin's lymphoma: a randomized multicenter study of 132 patients. The PETHEMA group. Program for Study and Therapeutics of malignant hemopathies. Spanish Association of Hematology and Hemotherapy].
López-Guillermo A; García-Conde J; Alvarez-Carmona AM; León P; Maldonado J; Alcalá A; Zubizarreta A; Sancho-Tello R; Carbonell F; Contreras E; Besses C; Hernando A; Fontanillas M; Montserrat E
Med Clin (Barc); 1998 May; 110(16):601-4. PubMed ID: 9656196
[TBL] [Abstract][Full Text] [Related]
20. [MTX-HOPE (methotrexate, hydrocortisone, vincristine, sobuzoxane, and etoposide) as a low-dose salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma].
Tsunoda S; Kobayashi H; Inoue K; Izumi T; Akutsu M; Katano S; Ueda T; Shirai T; Masuda Y; Ohmine K; Nagashima T; Ueda M; Takagi S; Muroi K; Ozawa K; Kano Y
Gan To Kagaku Ryoho; 2007 Jun; 34(6):885-9. PubMed ID: 17565251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]